Garrett M Frampton

Citado por

	Total	Desde 2019
Citas	42558	28286
Índice h	83	74
Índice i10	175	162

6000

3000

1500

4500

20082009201020112012201320142015201620172018201920202021202220232024142 254 379 635 865 1182 1293 1487 1837 2543 3112 3754 4809 5758 5373 5104 3455

Acceso público

Ver todo

95 artículos

0 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Alexa SchrockDirección de correo verificada de foundationmedicine.com
Zachary R ChalmersNorthwestern UniversityDirección de correo verificada de northwestern.edu
James X. SunDirección de correo verificada de mit.edu
Doron LipsonCSO, Ultima GenomicsDirección de correo verificada de ultimagen.com
Lee AlbackerDirector, Foundation Medicine Inc.Dirección de correo verificada de foundationmedicine.com
Richard YoungProfessor of Biology, MITDirección de correo verificada de wi.mit.edu
Razelle Kurzrock, MDProfessor of Medicine, Medical College of WisconsinDirección de correo verificada de mcw.edu
Roman YelenskyCTO, Gritstone OncologyDirección de correo verificada de gritstone.com
Sai-Hong Ignatius OuUniversity of California IrvineDirección de correo verificada de uci.edu
Samuel Klempner, MDMassachusetts General Hospital, Harvard Medical SchoolDirección de correo verificada de partners.org
Matthew GuentherSyros PharmaceuticalsDirección de correo verificada de wi.mit.edu
Stuart S. LevineMassachusetts Institute of TechnologyDirección de correo verificada de mit.edu
Albert W. Cheng, PhD 郑瑚博士Professor at Institute of Zoology, Chinese Academy of SciencesDirección de correo verificada de cheng.bio
Alexander MarsonDirector of Gladstone-UCSF Institute of Genomic Immunology, Professor, Department of MedicineDirección de correo verificada de ucsf.edu
Eric M SanfordIcahn School of Medicine at Mount Sinai, Department of PsychiatryDirección de correo verificada de mountsinai.org
David OrlandoMOMA TherapeuticsDirección de correo verificada de momatx.com
Steve BilodeauCentre de Recherche du CHU de Québec - Université LavalDirección de correo verificada de ulaval.ca
Sumeet GuptaWhitehead Institute Of Biomedical ResearchDirección de correo verificada de wi.mit.edu
Funda Meric-BernstamChair, Department of Investigational Cancer Therapeutics, The UT MD Anderson Cancer CenterDirección de correo verificada de mdanderson.org
Christopher LengnerUniversity of PennsylvaniaDirección de correo verificada de vet.upenn.edu

Seguir

Garrett M Frampton

Foundation Medicine Inc.

Dirección de correo verificada de foundationmedicine.com

Genomics Bioinformatics Computational biology Cancer genomics


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Histone H3K27ac separates active from poised enhancers and predicts developmental state MP Creyghton, AW Cheng, GG Welstead, T Kooistra, BW Carey, ... Proceedings of the National Academy of Sciences 107 (50), 21931-21936, 2010	4484	2010
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm … JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ... The Lancet 387 (10031), 1909-1920, 2016	3803	2016
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ... Genome medicine 9, 1-14, 2017	3065	2017
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing GM Frampton, A Fichtenholtz, GA Otto, K Wang, SR Downing, J He, ... Nature biotechnology 31 (11), 1023-1031, 2013	2233	2013
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers AM Goodman, S Kato, L Bazhenova, SP Patel, GM Frampton, V Miller, ... Molecular cancer therapeutics 16 (11), 2598-2608, 2017	2140	2017
Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells A Marson, SS Levine, MF Cole, GM Frampton, T Brambrink, S Johnstone, ... cell 134 (3), 521-533, 2008	1782	2008
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018	1312	2018
Densely interconnected transcriptional circuits control cell states in human hematopoiesis N Novershtern, A Subramanian, LN Lawton, RH Mak, WN Haining, ... Cell 144 (2), 296-309, 2011	1073	2011
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies D Lipson, M Capelletti, R Yelensky, G Otto, A Parker, M Jarosz, JA Curran, ... Nature medicine 18 (3), 382-384, 2012	1072	2012
Foxp3 occupancy and regulation of key target genes during T-cell stimulation A Marson, K Kretschmer, GM Frampton, ES Jacobsen, JK Polansky, ... Nature 445 (7130), 931-935, 2007	961	2007
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015	816	2015
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ... Cancer discovery 5 (8), 850-859, 2015	760	2015
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014	698	2014
Enhancer decommissioning by LSD1 during embryonic stem cell differentiation WA Whyte, S Bilodeau, DA Orlando, HA Hoke, GM Frampton, CT Foster, ... Nature 482 (7384), 221-225, 2012	643	2012
Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells MG Guenther, GM Frampton, F Soldner, D Hockemeyer, M Mitalipova, ... Cell stem cell 7 (2), 249-257, 2010	564	2010
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity H Beltran, R Yelensky, GM Frampton, K Park, SR Downing, ... European urology 63 (5), 920-926, 2013	555	2013
Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020	499	2020
Targeted next generation sequencing identifies markers of response to PD-1 blockade DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ... Cancer immunology research 4 (11), 959-967, 2016	472	2016
Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations CJ Lengner, AA Gimelbrant, JA Erwin, AW Cheng, MG Guenther, ... Cell 141 (5), 872-883, 2010	468	2010
Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small cell lung cancer using a clinicogenomic database G Singal, PG Miller, V Agarwala, G Li, G Kaushik, D Backenroth, A Gossai, ... Jama 321 (14), 1391-1399, 2019	456	2019

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores